Answers are grounded in this paper and cite their sources.
Preclinical animal study demonstrates 1,3-diacylglycerol improves glycemic control and lipid profiles in diabetic rats, indicating therapeutic potential via gut-signaling pathways.
taxa showed positive correlations with low-density lipoprotein cholesterol (LDL-C) and negative correlations with high-density lipoprotein cholesterol (HDL-C). 1,3-DAG significantly improved glycemic control, lipid metabolism and intestinal barrier integrity in T2DM rats. These benefits may be mediated through the gut microbiota-SCFA-GPR41-GLP-1 signaling axis. The findings suggest that 1,3-DAG is a promising dietary intervention for T2DM. Further clinical studies are warranted to validate its long-term efficacy and therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: